Starpharma logo

Starpharma(OTC) SPHRY

Market Cap$275.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-8%
5 Year-36%
1 Year+186%
1 Month-1%
$5.75
+1.77%
+0.10Today
Starpharma last closing stock price
MetricPriceDate
Last closeUSD 5.752026-10-08
Starpharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.71%USD 5.852026-10-01
1 month-0.86%USD 5.802026-09-08
3 month+20.75%USD 4.762026-07-07
Year to date+137.11%USD 2.432025-12-30
1 year+186.07%USD 2.012025-10-08
3 year+495.18%USD 0.972023-10-09
5 year-36.18%USD 9.012021-10-08
Since inception-7.75%USD 6.232005-01-20

Starpharma Financials at a Glance

Market Cap

$275.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$16.01M

Net Income (TTM)

-A$15.31M

EPS (TTM)

-$0.12

P/E Ratio

-46.82

Dividend

$0.00

Beta (Volatility)

0.27 (Low)

Price

$5.75

Volume

1,025

Open

$5.75

Previous Close

$5.75

Daily Range

$5.75 - $5.75

52-Week Range

$1.75 - $5.98

Estimated Earnings Date

Aug 26, 2026

SPHRY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Starpharma

Starpharma Holdings Limited is an Australian biopharmaceutical company focused on advancing proprietary dendrimer technology across various sectors, including pharmaceuticals and life sciences. The company offers innovative products such as VivaGel, an effective treatment for bacterial vaginosis, and VIRALEZE, an antiviral nasal spray.

Products and Services
  • VivaGel: Non-antibiotic treatment for bacterial vaginosis
  • VIRALEZE: Antiviral nasal spray for respiratory infections
  • DEP platform: Dendrimer drug delivery system with multiple oncology candidates
Growth Outlook
  • DEP dendrimer technology shows promise in oncology, with several candidates in Phase II trials
  • Recent partnerships enhance product development and market reach
  • Strong pipeline supports potential for future revenue growth
Financial Highlights
  • Recent quarterly revenue of 1,235,188 AUD, indicating market traction
  • Cash and cash equivalents of 11,015,625 AUD, providing operational stability
  • Trailing twelve months (TTM) gross profit margin of 86.26%, reflecting product viability
Starpharma Holdings Limited is positioned in the biotechnology sector, leveraging its innovative dendrimer technology to develop unique healthcare solutions. The company's product offerings, including VivaGel and VIRALEZE, address significant health challenges, particularly in women's health and viral infections. The DEP platform further enhances the company's capabilities in drug delivery, particularly for oncology treatments, which are currently in advanced clinical trials. The growth outlook for Starpharma is bolstered by its strong pipeline and strategic partnerships, which are expected to drive future revenue growth. Recent financial performance indicates a solid foundation, with a notable gross profit margin and sufficient cash reserves to support ongoing operations and development initiatives. As the company continues to innovate and expand its market presence, it remains a noteworthy player in the biopharmaceutical landscape.
AI Generated • Sep 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

50

CEO

Cheryl Maley, MBA

Website

www.starpharma.com

Headquarters

Abbotsford, VIC 3067, AU

SPHRY Financials

Key Financial Metrics (TTM)

Gross Margin

86.26%

Operating Margin

-159.60%

Net Income Margin

-61.95%

Return on Equity

-42.35%

Return on Capital

-129.88%

Return on Assets

-39.25%

Earnings Yield

-2.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$275.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.97M

Volume

1.02K

Avg. Volume

820.015

Financials (TTM)

Gross Profit

A$7.22M

Operating Income

-A$36.26M

EBITDA

-A$25.61M

Operating Cash Flow

-A$6.49M

Capital Expenditure

-A$320.54K

Free Cash Flow

-A$6.82M

Cash & ST Invst.

A$11.02M

Total Debt

A$707.04K

Starpharma Performance Analysis

Starpharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,977,079-41.8%
20242024-06-30AUD 5,432,404174.8%
20252025-06-30AUD 3,181,163-41.4%
20262026-06-30AUD 8,165,356156.7%
Starpharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3140.2%
Q42025-06-30-29.5%
Q22025-12-31521.3%
Q42026-06-30-88.4%
Starpharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.25-10.7%
20242024-06-30AUD -0.13-49.4%
20252025-06-30AUD -0.1519.3%
20262026-06-30AUD -0.12-22.3%
Starpharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3124.9%
Q42025-06-3057.7%
Q22025-12-31158.2%
Q42026-06-30-731.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$1.24M

-28.6%

Gross Profit

A$360.01K

+110.3%

Gross Margin

29.15%

N/A

Market Cap

$275.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.52M

N/A

Employees

50

N/A

Net Income

-A$8.96M

-25.6%

EBITDA

-A$15.54M

-136.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$11.02M

-52.8%

Total Debt

A$707.04K

-80.0%

Accounts Receivable

A$4.39M

-30.8%

Inventory

A$1.66M

-31.3%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$707.04K

-55.0%

Return on Assets

-39.25%

N/A

Return on Invested Capital

-1.39%

N/A

Free Cash Flow

-A$7.02M

+23.3%

Operating Cash Flow

-A$6.95M

+23.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,759.13-0.01%
^DJIDJI
$51,137.63-0.00%
^IXICNASDAQ
$27,193.56-0.01%
BTCBitcoin
$81,044.00-0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$142.52-10.31%
NOKNokia
$10.14-4.52%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.37+4.05%

Questions About SPHRY

What is the current price of Starpharma?

Starpharma is trading at $5.75 per share.

What is the 52-week range for Starpharma?

Over the past 52 weeks, Starpharma has traded between $1.75 and $5.98.

How much debt does Starpharma have?

As of the most recent reporting period, Starpharma reported total debt of A$489.81K.

How much cash does Starpharma have on hand?

Starpharma reported A$7.63M in cash and cash equivalents in its most recent financial results.

What is Starpharma’s dividend yield?

Starpharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services